AlphaYou
Overview
Smart money at a glance
Filings to Oct 12, 2026Net selling: insiders sold $780K and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
- Company insidersSEC Form 4, last 90 days
- -$780K netNet selling
- CongressSTOCK Act, last 180 days
- NoneNo trades disclosed
- Big fundsSEC 13F, quarter ended Jun 30, 2026
- 1 added, 0 cutMore adding
- Federal contractsUSAspending.gov, last 12 months
- No awardsNone on record
Market overview
Fundamentals Oct 12- Open
- $15.41
- 52-wk high
- $23.19
- High
- $15.95
- 52-wk low
- $6.73
- Low
- $15.24
- Prev close
- $15.46
- Mkt cap
- $954.4M
- Volume
- 567.5K
- Fwd P/E
- 6.7x
- Beta
- -0.04
- P/S
- 25.9x
- P/B
- 3.4x
- Profit margin
- +0.0%
- Op margin
- +0.0%
- ROE
- -50.3%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsQuestions about CGEM filings
Are insiders buying or selling Cullinan Oncology LLC (CGEM) stock?
Net selling: insiders sold $780K and bought $0 of CGEM stock on the open market in the 90 days to Oct 12, 2026, according to SEC Form 4 filings. $780K of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Michaelson, Jennifer (Chief Scientific Officer), who sold $780K. The latest filing was on Sep 10, 2026.
Which members of Congress have traded CGEM recently?
None. No member of Congress disclosed a CGEM trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
How current is this CGEM smart-money data?
This summary uses filings available on Oct 12, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
Smart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Buys/Adds (1)
- AQ
AQR
$5.5M
added
What insiders are doing
How top traders are positioned
No tracked top-trader positions in CGEM right now.
Live Hyperliquid positioning - not every stock is covered
Earnings
Earnings came in 4.9% above what analysts expected.
Last report
Aug 6, 2026
Period ending
Jun 30, 2026
Adjusted EPS
-$0.85 expected
Revenue
No reported revenue on record
Previous reports
All values in USD| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 6, 2026 | -$0.81 / -$0.85Yahoo Finance | +4.85% beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 7, 2026 | -$0.75 / -$0.84Yahoo Finance | +11.06% beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 10, 2026 | -$0.77 / -$0.84Yahoo Finance | +8.21% beat | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 6, 2025 | -$0.77 / -$0.89Yahoo Finance | +13.68% beat | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 7, 2025 | -$1.07 / -$0.83Alpha Vantage | -28.92% miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 8, 2025 | -$0.74 / -$0.81Alpha Vantage | +8.64% beat | Unavailable | Unavailable |
| Dec 31, 2024 | Feb 27, 2025 | -$0.73 / -$0.74Alpha Vantage | +1.66% beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 7, 2024 | -$0.69 / -$0.77Alpha Vantage | +10.39% beat | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
Reports Nov 5, 2026, in 24 days
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $0 | $0 | $0 | $0 |
| Cost of what it sold | — | $79.0K | $79.0K | — |
| Gross profit | — | -$79.0K | -$79.0K | — |
| What it spent | ||||
| Research and development | $42.0M | $42.9M | $42.1M | $44.4M |
| Sales and admin | $13.6M | $12.3M | $11.6M | $12.8M |
| Total operating expenses | $55.6M | $55.3M | $53.7M | $57.3M |
| What was left | ||||
| Operating profit | -$55.6M | -$55.3M | -$53.7M | -$57.3M |
| Profit before tax | -$50.6M | -$50.7M | -$49.7M | -$53.7M |
| Net profit | -$50.6M | -$50.7M | -$49.7M | -$53.7M |
| EBITDA | -$50.5M | -$50.6M | -$53.6M | -$53.6M |
Technicals
Price structure
This stock is under pressure, and looks oversold after a sharp drop.
Trend
Under pressure
25 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace